Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cloretazine in Refractory/Relapsed CLL or Richter's Syndrome
NCT00304005Phase 2Completed
- Sponsor
- Vion Pharmaceuticals
- Start
- Jul 2005
- Primary completion
- Oct 2005
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of laromustine in chronic lymphocytic leukemia (CLL) and Richter's syndrome (RS), sponsored by Vion Pharmaceuticals. Primary endpoints: Maximum Tolerated Dose, Toxic Effects and 1 more. Started Jul 2005; status: completed.
02
Drugs
laromustine
03
Conditions
chronic lymphocytic leukemia (CLL)Richter's syndrome (RS)
Beyond the preview
Go deeper on NCT00304005.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00304005.